Advertisement

Topics

Evenity (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

21:09 EDT 10 Sep 2017 | Drugs.com

THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of Evenity™* (romosozumab) followed by...

Original Article: Evenity (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

NEXT ARTICLE

More From BioPortfolio on "Evenity (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...